Back to search
FDAFDA · Food and drugs·Recall number D-0437-2026

5% Dextrose Injection, USP 12.5 g per 250 mL (50 mg per mL) 250 mL in a 250 mL freeflex bag, Fresenius Kabi USA, LLC ("Fresenius Kabi"), Unit of Use NDC: 65219-458-05, Unit of Sale NDC Number: 65219-458-30.

Published April 15, 2026 · Recall initiated: March 11, 2026

Summary

FDA records drug Class II recall D-0437-2026, published April 15, 2026 and initiated March 11, 2026. Recalling firm: Fresenius Kabi USA, LLC; Status: Ongoing; Lot: Batch# 6402165, Exp Date: 05/30/2028. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Lack of Assurance of Sterility

What to do

Voluntary: Firm initiated · Letter

Get an email if DEXTROSE has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
DEXTROSE
Manufacturer
Fresenius Kabi USA, LLC
Distributor
US Nationwide , Alaska, and Puerto Rico.
Lot
Batch# 6402165, Exp Date: 05/30/2028.
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was 5% Dextrose Injection, USP 12.5 g per 250 mL (50 mg per mL) 250 mL in a 250 mL freeflex bag, Fresenius Kabi USA, LLC ("Fresenius Kabi"), Unit of Use NDC: 65219-458-05, Unit of Sale NDC Number: 65219-458-30. recalled?

Yes. FDA published recall D-0437-2026 on April 15, 2026. Reported hazard: Lack of Assurance of Sterility

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: DEXTROSE.